Nanobiomaterials in cancer therapy

Nanobiomaterials in Cancer Therapy: Applications of Nanobiomaterials

Volumn , Issue , 2016, Pages 57-89

  Srinivasan, Mathangi ^a   Rajabi, Mehdi ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Active targeting; Cancer stem cells; Chemotherapy; EPR; Multifunctional nanoparticles; Nanochemoprevention

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; MEDICAL IMAGING; NANOPARTICLES; ONCOLOGY; PARAMAGNETIC RESONANCE; STEM CELLS; TOXICITY;

ACTIVE TARGETING; CANCER STEM CELLS; CANCER THERAPEUTICS; CHEMOTHERAPEUTIC DRUGS; MULTI-FUNCTIONAL NANOPARTICLES; NANOCHEMOPREVENTION; SYSTEMIC TOXICITIES; TUMOR-SPECIFIC TARGETING;

TARGETED DRUG DELIVERY;

EID: 84969132879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-42863-7.00003-7     Document Type: Chapter

References (149)

1. Avgoustakis, K., Beletsi, A., Panagi, Z., Klepetsanis, P., Karydas, A.G., Ithakissios, D.S., 2002. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release 79, 123-135.
2. Baker, J., Ajani, J., Scotte, F., Winther, D., Martin, M., Aapro, M.S., et al., 2008. Docetaxelrelated side effects and their management. Eur. J. Oncol. Nurs. 12, 253-268.
3. Banzato, A., Bobisse, S., Rondina, M., Renier, D., Bettella, F., Esposito, G., et al., 2008. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 14, 3598-3606.
4. Barras, A., Mezzetti, A., Richard, A., Lazzaroni, S., Roux, S., Melnyk, P., et al., 2009. Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int. J. Pharm. 379, 270-277.
5. Bertrand, N., Wu, J., Xu, X., Kamaly, N., Farokhzad, O.C., 2014. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25.
6. Bharali, D.J., Mousa, S.A., 2010. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther. 128, 324-335.
7. Bharali, D.J., Lucey, D.W., Jayakumar, H., Pudavar, H.E., Prasad, P.N., 2005. Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J. Am. Chem. Soc. 127, 11364-11371.
8. Bharali, D.J., Siddiqui, I.A., Adhami, V.M., Chamcheu, J.C., Aldahmash, A.M., Mukhtar, H., et al., 2011. Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers (Basel) 3, 4024-4045.
9. Bharali, D.J., Yalcin, M., Davis, P.J., Mousa, S.A., 2013. Tetraiodothyroacetic acidconjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond) 8, 1943-1954.
10. Bhat, K.P., Lantvit, D., Christov, K., Mehta, R.G., Moon, R.C., Pezzuto, J.M., 2001. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61, 7456-7463.
11. Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., et al., 2007. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol. 5, 3.
12. Biswas, S., Deshpande, P.P., Navarro, G., Dodwadkar, N.S., Torchilin, V.P., 2013. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials 34, 1289-1301.
13. Boulikas, T., Vougiouka, M., 2003. Cisplatin and platinum drugs at the molecular level. (Review). Oncol. Rep. 10, 1663-1682.
14. Bourseau-Guilmain, E., Bejaud, J., Griveau, A., Lautram, N., Hindre, F., Weyland, M., et al., 2012. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int. J. Pharm. 423, 93-101.
15. Brigger, I., Dubernet, C., Couvreur, P., 2002. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651.
16. Bronich, T.K., Keifer, P.A., Shlyakhtenko, L.S., Kabanov, A.V., 2005. Polymer micelle with cross-linked ionic core. J. Am. Chem. Soc. 127, 8236-8237.
17. Burke, P.A., Denardo, S.J., Miers, L.A., Lamborn, K.R., Matzku, S., Denardo, G.L., 2002. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62, 4263-4272.
18. Chen, S., Zhao, D., Li, F., Zhuo, R.X., Cheng, S.X., 2012. Co-delivery of genes and drugs with nanostructured calcium carbonate for cancer therapy. Rsc Adv. 2, 1820-1826.
19. Chen, T.J., Cheng, T.H., Chen, C.Y., Hsu, S.C., Cheng, T.L., Liu, G.C., et al., 2009. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J. Biol. Inorg. Chem. 14, 253-260.
20. Creixell, M., Peppas, N.A., 2012. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 7, 367-379.
21. Cuvier, C., Roblot-Treupel, L., Millot, J.M., Lizard, G., Chevillard, S., Manfait, M., et al., 1992. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44, 509-517.
22. Das, R.K., Kasoju, N., Bora, U., 2010. Encapsulation of curcumin in alginate-chitosanpluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 6, 153-160.
23. Davis, P.J., Mousa, S.A., Cody, V., Tang, H.Y., Lin, H.Y., 2013. Small molecule hormone or hormone-like ligands of integrin alphaVbeta3: implications for cancer cell behavior. Horm Cancer 4, 335-342.
24. Davis, P.J., Lin, H.Y., Sudha, T., Yalcin, M., Tang, H.Y., Hercbergs, A., et al., 2014. Nanotetrac targets integrin alphavbeta3 on tumor cells to disorder cell defense pathways and block angiogenesis. Onco Targets Ther. 7, 1619-1624.
25. Deng, C., Jiang, Y.J., Cheng, R., Meng, F.H., Zhong, Z.Y., 2012. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 7, 467-480.
26. Dube, A., Nicolazzo, J.A., Larson, I., 2010. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (1)-catechin and (2)-epigallocatechin gallate. Eur. J. Pharm. Sci. 41, 219-225.
27. Dumontet, C., Sikic, B.I., 1999. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17, 1061-1070.
28. Eckhoff, L., Nielsen, M., Moeller, S., Knoop, A., 2011. TAXTOX-a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007-2009. Acta Oncol. 50, 1075-1082.
29. Egea, M.A., Gamisans, F., Valero, J., Garcia, M.E., Garcia, M.L., 1994. Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticles. Farmaco 49, 211-217.
30. Felber, A.E., Dufresne, M.H., Leroux, J.C., 2012. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv. Drug Deliv. Rev. 64, 979-992.
31. Fonseca, C., Simoes, S., Gaspar, R., 2002. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release 83, 273-286.
32. Gajbhiye, V., Jain, N.K., 2011. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 32, 6213-6225.
33. Gao, X., Yang, L., Petros, J.A., Marshall, F.F., Simons, J.W., Nie, S., 2005. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16, 63-72.
34. Gindy, M.E., Prud'homme, R.K., 2009. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin. Drug Deliv. 6, 865-878.
35. Glinskii, A.B., Glinsky, G.V., Lin, H.Y., Tang, H.Y., Sun, M., Davis, F.B., et al., 2009. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8, 3562-3570.
36. Gluck, S., 2014. nab-Paclitaxel for the treatment of aggressive metastatic breast cancer. Clin. Breast Cancer 14, 221-227.
37. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et al., 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803.
38. Graf, N., Bielenberg, D.R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O.C., et al., 2012. Alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced antitumor efficacy of a Pt(IV) prodrug. ACS Nano 6, 4530-4539.
39. Gryparis, E.C., Hatziapostolou, M., Papadimitriou, E., Avgoustakis, K., 2007. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur. J. Pharm. Biopharm. 67, 1-8.
40. Guo, L., Peng, Y., Yao, J., Sui, L., Gu, A., Wang, J., 2010. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother. Radiopharm. 25, 471-477.
41. Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., et al., 2009. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659.
42. Han, H.D., Mangala, L.S., Lee, J.W., Shahzad, M.M., Kim, H.S., Shen, D., et al., 2010. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 16, 3910-3922.
43. Harikumar, K.B., Kunnumakkara, A.B., Sethi, G., Diagaradjane, P., Anand, P., Pandey, M.K., et al., 2010. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer 127, 257-268.
44. Hatcher, H., Planalp, R., Cho, J., Torti, F.M., Torti, S.V., 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol. Life. Sci. 65, 1631-1652.
45. Heisig, P., 2009. Type II topoisomerases-inhibitors, repair mechanisms and mutations. Mutagenesis 24, 465-469.
46. Hrkach, J., Von Hoff, D., Mukkaram Ali, M., Andrianova, E., Auer, J., Campbell, T., et al., 2012. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra39.
47. Huang, H.C., Barua, S., Sharma, G., Dey, S.K., Rege, K., 2011. Inorganic nanoparticles for cancer imaging and therapy. J. Control. Release 155, 344-357.
48. Ibrahim, N.K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R.L., Rivera, E., et al., 2002. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044.
49. Janes, K.A., Fresneau, M.P., Marazuela, A., Fabra, A., Alonso, M.J., 2001. Chitosan nanoparticles as delivery systems for doxorubicin. J. Control. Release 73, 255-267.
50. Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., et al., 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220.
51. Jia, F., Liu, X., Li, L., Mallapragada, S., Narasimhan, B., Wang, Q., 2013. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Control. Release 172, 1020-1034.
52. Jiang, G., Park, K., Kim, J., Kim, K.S., Hahn, S.K., 2009. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol. Pharm. 6, 727-737.
53. Johnson, J.J., Mukhtar, H., 2007. Curcumin for chemoprevention of colon cancer. Cancer Lett. 255, 170-181.
54. Jordan, C.T., Guzman, M.L., Noble, M., 2006. Cancer stem cells. N. Engl. J. Med. 355, 1253-1261.
55. Khan, N., Mukhtar, H., 2013. Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem. Pharmacol. 85, 667-672.
56. Kievit, F.M., Zhang, M., 2011. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res. 44, 853-862.
57. Kikumori, T., Kobayashi, T., Sawaki, M., Imai, T., 2009. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res. Treat. 113, 435-441.
58. Kim, J.H., Kim, Y.S., Park, K., Lee, S., Nam, H.Y., Min, K.H., et al., 2008. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 127, 41-49.
59. Kirpotin, D.B., Drummond, D.C., Shao, Y., Shalaby, M.R., Hong, K., Nielsen, U.B., et al., 2006. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732-6740.
60. Kobayashi, H., Brechbiel, M.W., 2003. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol. Imaging 2, 1-10.
61. Kojima, C., Kono, K., Maruyama, K., Takagishi, T., 2000. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 11, 910-917.
62. Lammers, T., Kiessling, F., Hennink, W.E., Storm, G., 2012. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161, 175-187.
63. Lawrie, T.A., Bryant, A., Cameron, A., Gray, E., Morrison, J., 2013. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst. Rev. 7, CD006910.
64. Lee, A.L., Wang, Y., Pervaiz, S., Fan, W., Yang, Y.Y., 2011a. Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. Macromol. Biosci. 11, 296-307.
65. Lee, K.W., Bode, A.M., Dong, Z., 2011b. Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer 11, 211-218.
66. Li, W., Zhao, M., Ke, C., Zhang, G., Zhang, L., Li, H., et al., 2013. Nano polymeric carrier fabrication technologies for advanced antitumor therapy. Biomed. Res. Int. 2013, 305089.
67. Liebmann, J., Cook, J.A., Mitchell, J.B., 1993. Cremophor EL, solvent for paclitaxel, and toxicity. Lancet 342, 1428.
68. Lien, M.Y., Liu, L.C., Wang, H.C., Yeh, M.H., Chen, C.J., Yeh, S.P., et al., 2014. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. Anticancer Res. 34, 7319-7326.
69. Lin, Y.Y., Kao, H.W., Li, J.J., Hwang, J.J., Tseng, Y.L., Lin, W.J., et al., 2013. Tumor burden talks in cancer treatment with PEGylated liposomal drugs. PLoS One 8, e63078.
70. Liu, Z., Wang, Y., Zhang, N., 2012. Micelle-like nanoassemblies based on polymer-drug conjugates as an emerging platform for drug delivery. Expert Opin. Drug Deliv. 9, 805-822.
71. Longhi, A., Ferrari, S., Bacci, G., Specchia, S., 2007. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 18, 737-744.
72. Lu, J.M., Wang, X., Marin-Muller, C., Wang, H., Lin, P.H., Yao, Q., et al., 2009. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9, 325-341.
73. Lu, Y., Low, P.S., 2002. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54, 675-693.
74. MacDonald, T.J., Vezina, G., Stewart, C.F., Turner, D., Pierson, C.R., Chen, L., et al., 2013. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the children's oncology group. Neuro. Oncol. 15, 1438-1444.
75. Maeda, H., Sawa, T., Konno, T., 2001. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74, 47-61.
76. Maeda, H., Bharate, G.Y., Daruwalla, J., 2009. Polymeric drugs for efficient tumortargeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71, 409-419.
77. Mamaeva, V., Rosenholm, J.M., Bate-Eya, L.T., Bergman, L., Peuhu, E., Duchanoy, A., et al., 2011. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol. Ther. 19, 1538-1546.
78. Matchett, K.B., Lappin, T.R., 2014. Concise reviews: cancer stem cells: from concept to cure. Stem Cells 32, 2563-2570.
79. Matsumura, Y., Maeda, H., 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392.
80. Megerdichian, C., Olimpiadi, Y., Hurvitz, S.A., 2014. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat. Rev. 40, 614-625.
81. Mei, L., Liu, Y., Zhang, Q., Gao, H., Zhang, Z., He, Q., 2014. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin. J. Control. Release 196, 324-331.
82. Miao, L., Guo, S., Zhang, J., Kim, W.Y., Huang, L., 2014. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv. Funct. Mater. 24, 6601-6611.
83. Michalet, X., Pinaud, F.F., Bentolila, L.A., Tsay, J.M., Doose, S., Li, J.J., et al., 2005. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544.
84. Milane, L., Duan, Z., Amiji, M., 2011. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm. 8, 185-203.
85. Milla, P., Dosio, F., Cattel, L., 2012. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr. Drug Metab. 13, 105-119.
86. Mimeault, M., Batra, S.K., 2011. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin. Med. 6, 31.
87. Minko, T., Rodriguez-Rodriguez, L., Pozharov, V., 2013. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv. Drug Deliv. Rev. 65, 1880-1895.
88. Misra, R., Sahoo, S.K., 2011. Coformulation of doxorubicin and curcumin in poly(D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol. Pharm. 8, 852-866.
89. Mousa, S.A., Yalcin, M., Bharali, D.J., Meng, R., Tang, H.Y., Lin, H.Y., et al., 2012. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 76, 39-45.
90. Murakami, H., Kobayashi, M., Takeuchi, H., Kawashima, Y., 1999. Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 187, 143-152.
91. Nabors, L.B., Mikkelsen, T., Rosenfeld, S.S., Hochberg, F., Akella, N.S., Fisher, J.D., et al., 2007. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25, 1651-1657.
92. Narayanan, N.K., Nargi, D., Randolph, C., Narayanan, B.A., 2009. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 125, 1-8.
93. Nazir, S., Hussain, T., Ayub, A., Rashid, U., Macrobert, A.J., 2014. Nanomaterials in combating cancer: therapeutic applications and developments. Nanomedicine 10, 19-34.
94. Oberoi, H.S., Laquer, F.C., Marky, L.A., Kabanov, A.V., Bronich, T.K., 2011. Core cross-linked block ionomer micelles as pH-responsive carriers for cis-diamminedichloroplatinum(II). J. Control. Release 153, 64-72.
95. Oki, Y., Ewer, M.S., Lenihan, D.J., Fisch, M.J., Hagemeister, F.B., Fanale, M., et al., 2014. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard RCHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin. Lymphoma Myeloma Leuk 15 (3), 152-158.
96. Olavarria, E., et al., 2000. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 14 (11), 1954-1959.
97. Onyuksel, H., Jeon, E., Rubinstein, I., 2009. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 274, 327-330.
98. Park, J., Ayyappan, V., Bae, E.K., Lee, C., Kim, B.S., Kim, B.K., et al., 2008. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol. Oncol. 2, 317-326.
99. Patri, A.K., Kukowska-Latallo, J.F., Baker JR, J.R., 2005. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and noncovalent drug inclusion complex. Adv. Drug Deliv. Rev. 57, 2203-2214.
100. Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., et al., 2013. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412-2417.
101. Prajakta, D., Ratnesh, J., Chandan, K., Suresh, S., Grace, S., Meera, V., et al., 2009. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J. Biomed. Nanotechnol. 5, 445-455.
102. Prencipe, G., Tabakman, S.M., Welsher, K., Liu, Z., Goodwin, A.P., Zhang, L., et al., 2009. PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. J. Am. Chem. Soc. 131, 4783-4787.
103. Reardon, D.A., Fink, K.L., Mikkelsen, T., Cloughesy, T.F., O'neill, A., Plotkin, S., et al., 2008. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycineaspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610-5617.
104. Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., 2001. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
105. Sahoo, S.K., Ma, W., Labhasetwar, V., 2004. Efficacy of transferrin-conjugated paclitaxelloaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 112, 335-340.
106. Sahu, A., Bora, U., Kasoju, N., Goswami, P., 2008. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 4, 1752-1761.
107. Sanna, V., Sechi, M., 2012. Nanoparticle therapeutics for prostate cancer treatment. Maturitas 73, 27-32.
108. Sanna, V., Siddiqui, I.A., Sechi, M., Mukhtar, H., 2013. Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett. 334, 142-151.
109. Saunders, F.R., Wallace, H.M., 2010. On the natural chemoprevention of cancer. Plant Physiol. Biochem. 48, 621-626.
110. Schroeder, J.E., Shweky, I., Shmeeda, H., Banin, U., Gabizon, A., 2007. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles. J. Control. Release 124, 28-34.
111. Shao, J., Li, X., Lu, X., Jiang, C., Hu, Y., Li, Q., et al., 2009. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf. B Biointerfaces 72, 40-47.
112. Shervington, A., Lu, C., 2008. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 26, 535-542.
113. Shutava, T.G., Balkundi, S.S., Vangala, P., Steffan, J.J., Bigelow, R.L., Cardelli, J.A., et al., 2009. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 3, 1877-1885.
114. Siddiqui, I.A., Adhami, V.M., Bharali, D.J., Hafeez, B.B., Asim, M., Khwaja, S.I., et al., 2009. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 69, 1712-1716.
115. Socinski, M.A., Bondarenko, I., Karaseva, N.A., Makhson, A.M., Vynnychenko, I., Okamoto, I., et al., 2012. Weekly nab-paclitaxel in combination with carboplatin versus solventbased paclitaxel plus carboplatin as first-line therapy in patients with advanced non-smallcell lung cancer: final results of a phase III trial. J. Clin. Oncol. 30, 2055-2062.
116. Sorensen, K., Levitt, G.A., Bull, C., Dorup, I., Sullivan, I.D., 2003. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97, 1991-1998.
117. Sun, B., Ranganathan, B., Feng, S.S., 2008a. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29, 475-486.
118. Sun, C., Lee, J.S., Zhang, M., 2008b. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 60, 1252-1265.
119. Sun, C., Veiseh, O., Gunn, J., Fang, C., Hansen, S., Lee, D., et al., 2008c. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 4, 372-379.
120. Sun, T.M., Du, J.Z., Yao, Y.D., Mao, C.Q., Dou, S., Huang, S.Y., et al., 2011. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 5, 1483-1494.
121. Surh, Y.J., 2003. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer. 3, 768-780.
122. Swanson, S.D., Kukowska-Latallo, J.F., Patri, A.K., Chen, C., Ge, S., Cao, Z., et al., 2008. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine 3, 201-210.
123. Tan, Q., Liu, X., Fu, X., Li, Q., Dou, J., Zhai, G., 2012. Current development in nanoformulations of docetaxel. Expert Opin. Drug Deliv. 9, 975-990.
124. Thangapazham, R.L., Puri, A., Tele, S., Blumenthal, R., Maheshwari, R.K., 2008. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol. 32, 1119-1123.
125. Usmani, S.Z., Lonial, S., 2014. Novel drug combinations for the management of relapsed/ refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk 14S, S71-S77.
126. Valencia, P.M., Pridgen, E.M., Rhee, M., Langer, R., Farokhzad, O.C., Karnik, R., 2013. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano 7, 10671-10680.
127. Vinogradov, S., Wei, X., 2012. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 7, 597-615.
128. Visvader, J.E., Lindeman, G.J., 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768.
129. Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., et al., 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703.
130. Walko, C.M., McLeod, H., 2009. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat. Clin. Pract. Oncol. 6, 153-162.
131. Wang, A.Z., Bagalkot, V., Vasilliou, C.C., Gu, F., Alexis, F., Zhang, L., et al., 2008. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chem. Med. Chem. 3, 1311-1315.
132. Wang, J., Tian, S., Petros, R.A., Napier, M.E., Desimone, J.M., 2010. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc. 132, 11306-11313.
133. Wang, Y., Gao, S., Ye, W.H., Yoon, H.S., Yang, Y.Y., 2006. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5, 791-796.
134. Wei, X., Senanayake, T.H., Warren, G., Vinogradov, S.V., 2013. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug. Chem. 24, 658-668.
135. Weiss, R.B., Donehower, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., et al., 1990. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263-1268.
136. Win, K.Y., Feng, S.S., 2006. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 27, 2285-2291.
137. Wu, W., Shen, J., Banerjee, P., Zhou, S., 2010. Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemophotothermal treatment. Biomaterials 31, 7555-7566.
138. Xu, X., Xie, K., Zhang, X.Q., Pridgen, E.M., Park, G.Y., Cui, D.S., et al., 2013. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated of siRNA and cisplatin prodrug. Proc. Natl. Acad. Sci. USA 110, 18638-18643.
139. Yadav, V.R., Aggarwal, B.B., 2011. Curcumin: a component of the golden spice, targets multiple angiogenic pathways. Cancer Biol. Ther. 11, 236-241.
140. Yalcin, M., Bharali, D.J., Lansing, L., Dyskin, E., Mousa, S.S., Hercbergs, A., et al., 2009. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 29, 3825-3831.
141. Yalcin, M., Dyskin, E., Lansing, L., Bharali, D.J., Mousa, S.S., Bridoux, A., et al., 2010. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 95, 1972-1980.
142. Yalcin, M., Lin, H.Y., Sudha, T., Bharali, D.J., Meng, R., Tang, H.Y., et al., 2013. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm Cancer 4, 176-185.
143. Yano, J., Hirabayashi, K., Nakagawa, S., Yamaguchi, T., Nogawa, M., Kashimori, I., et al., 2004. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721-7726.
144. Yao, Q., Hou, S.X., He, W.L., Feng, J.L., Wang, X.C., Fei, H.X., et al., 2006. Study on the preparation of resveratrol chitosan nanoparticles with free amino groups on the surface. Zhongguo Zhong Yao Za Zhi 31, 205-208.
145. Yardley, D.A., 2013. nab-Paclitaxel mechanisms of action and delivery. J. Control. Release 170, 365-372.
146. Zhang, B., Jia, F., Fleming, M.Q., Mallapragada, S.K., 2012. Injectable self-assembled block copolymers for sustained gene and drug co-delivery: an in vitro study. Int. J. Pharm. 427, 88-96.
147. Zhang, L., Gu, F.X., Chan, J.M., Wang, A.Z., Langer, R.S., Farokhzad, O.C., 2008. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769.
148. Zhou, Q., et al., 2009. A randomized multicenter phase II clinical trial of mitoxantroneloaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine 5 (4), 419-423.
149. Zhu, C., Jung, S., Luo, S., Meng, F., Zhu, X., Park, T.G., et al., 2010. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 31, 2408-2416.